Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

被引：0

作者：

van de Donk, Niels W. C. J. ^{[1
]}

Chari, Ajai ^{[2
]}

Karlin, Lionel ^{[3
]}

Krishnan, Amrita Y. ^{[4
]}

Uttervall, Katarina ^{[5
]}

Chalopin, Thomas ^{[6
]}

Dachs, Laura Rosinol ^{[7
]}

Oriol, Albert ^{[8
,9
]}

Matous, Jeffrey, V ^{[10
]}

Bhutani, Manisha ^{[11
]}

Rodriguez, Cesar ^{[12
]}

Carde, Natalia Quijano ^{[13
]}

Guo, Yue ^{[13
]}

Hodin, Caroline ^{[14
]}

Uhlar, Clarissa ^{[13
]}

Stephenson, Tara ^{[13
]}

Zuppa, Athena ^{[15
]}

Doyle, Margaret ^{[16
]}

Chastain, Katherine ^{[15
]}

Garfall, Alfred ^{[17
]}

机构：

[1] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands

[2] Univ Calif San Francisco, San Francisco, CA USA

[3] Ctr Hosp Lyon Sud, Pierre Benite, France

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Karolinska Univ Hosp, Stockholm, Sweden

[6] Ctr Hosp Univ Tours, Tours, France

[7] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[8] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[9] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[10] Sarah Cannon Res Inst, Colorado Blood Canc Inst, Denver, CO USA

[11] Atrium Hlth, Levine Canc Inst, Wake Forest Sch Med, Charlotte, NC USA

[12] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med Hematol & Med Oncol, New York, NY USA

[13] Janssen Res & Dev, Spring House, PA USA

[14] Janssen Res & Dev, Beerse, Belgium

[15] Janssen Res & Dev, Raritan, NJ USA

[16] Janssen Global Serv, Dublin, Ireland

[17] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200344

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4735 / 4735

页数：1

共 34 条

[31] Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
Zonder, Jeffrey
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Cronier, Damien
Houvras, Yariv
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Madhav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S35
[32] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Zonder, Jeffrey A.
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Cronier, Damien
Houvras, Yariv
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Madhav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S406 - S407
[33] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Zonder, Jeffrey A.
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Sharma, Manish
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Mahdav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
BLOOD, 2021, 138
[34] Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human ( FIH) Phase 1 Trial
Gaballa, Sameh
Nair, Ranjit
Jacobs, Ryan W.
Devata, Sumana
Cho, Seok-Goo
Stevens, Don A.
Yoon, Dok Hyun
Shah, Nirav N.
Brennan, Denise
Law, Jason
Chen, Robert
Sermer, David
Lesley, Robin
Buelow, Ben
Forcina, Alessandra
Hou, Jing-Zhou
BLOOD, 2023, 142

← 1 2 3 4 →